CXCL11 and neoplasm: When assessed in vivo, the OV-CXCL11 and CAR T-cell combination further diminished tumor volume, significantly prolonged survival, increased CAR T-cell infiltration, and increased proinflammatory cytokine production (TNF-α and IFN-γ) compared to monotherapy alone.